#USA #Atlanta #Nordic Pharma #SECO 2025 #Lacrifill Gel

Nordic Pharma’s Presentation of Lacrifill® Canalicular Gel at SECO 2025

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., recently announced an exciting development in dry eye treatment—its participation in SECO 2025, one of the industry's most prestigious educational conferences. The event is scheduled to take place from February 26 to March 2, 2025, in Atlanta, Georgia. Among the highlights will be a poster presentation on Lacrifill® canalicular gel, presented by Dr. Mile Brujic, OD, FAAO, from Premier Vision Group.

The Lacrifill Canalicular Gel is a novel hyaluronic acid (HA) solution packaged in a single-use prefilled syringe. This innovative product can be injected into the canaliculus through the punctum using a specialized canula, an approach that represents a significant advancement in dry eye therapies. The poster will detail a case series involving three patients who previously experienced refractory dry eye and had undergone treatment with dissolvable canalicular plugs.

Dr. Brujic, who has directly observed the benefits of Lacrifill gel in his practice, expressed, “Lacrifill Canalicular Gel has proven to be something special for my patients. These cases highlight just a few individuals among many who have shown significant corneal improvement and comfort when treated with Lacrifill Canalicular Gel. Furthermore, I have been able to increase the number of occlusions I perform in my practice with the introduction of this gel.” This statement underlines the product's potential impact in the optometric field.

SECO International is noted for being among the largest educational gatherings for optometry worldwide, presenting unparalleled learning opportunities, cutting-edge exhibitions, and innovative networking chances. Phil Gioia, the president of the American team at Nordic Pharma, stated their enthusiasm for the ability of optometrists to administer Lacrifill gel as an intervention for dry eye, yielding favorable outcomes. “Since launching Lacrifill gel last year, we have partnered with vision care professionals and continue to support ophthalmologists in their essential role in managing dry eye,” Gioia remarked.

Presentation Details

The specifics of Dr. Brujic's presentation at SECO are as follows:

• - Title: New canalicular gel for lacrimal occlusion: Case series
• - Presenter: Mile Brujic, OD, FAAO
• - Date and Time: February 28, 9:45 AM - 11:45 AM
• - Location: Georgia World Congress Center, Hall A-1 and A-2, Building A-Level 1, Optometry's Marketplace™

All poster presentations will be made available online on SECO University following the event, enabling a broader audience to access the findings shared at the conference.

For more information on Lacrifill Canalicular Gel and ordering options, interested parties are encouraged to visit lacrifill.com.

About Nordic Group B.V.

Nordic Group B.V. is an international mid-sized pharmaceutical company dedicated to the development and marketing of specialized products. The organization has strategically enhanced its portfolio through targeted developments and acquisitions, thereby laying the groundwork for advancements in ophthalmology, rheumatology, and women’s health. With a significant presence throughout Europe and recent expansions beyond, Nordic Group is broadening its global reach.

Nordic Group forms part of SEVER Life Sciences, a holding established in 2019 that consolidates three complementary companies, offering an extensive array of products, pharmaceutical development services, and administration technologies.

About Nordic Pharma, Inc.

Nordic Pharma, Inc. stands out as a subsidiary of Nordic Group B.V., collaborating with established global biopharmaceutical companies. They harness their expertise in the market entry of biotechnology-derived medications and sterile manufacturing along with other advanced technologies.

Forward-Looking Statements

This press release may contain forward-looking statements related to Nordic Group/Nordic Pharma’s business developments and strategic initiatives. Since these statements reflect the current views, expectations, and beliefs, they entail risks and uncertainties that might result in actual developments and outcomes differing materially from Nordic Group/Nordic Pharma’s anticipations. Factors contributing to such deviations may include market conditions, regulatory trends, and other influences affecting the financial performance of Nordic Group/Nordic Pharma. The company does not undertake any obligation to publicly update its forward-looking statements based on new information or subsequent events.

For further inquiries, contact:

• - Kate Popova, Project Contracts Manager

Phone: 610-285-1699

• - Gail Feerrar, Sales and Marketing Director

Phone: 610-285-7152